LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX)

Q: What does CUSIP 528872302 represent in this 13F holders report?

CUSIP 528872302 is the security identifier for LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share in Q1 2026?

25 institutional investors reported LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share for Q1 2026. Use the holders table for investor-level position and value details.

CUSIP: 528872302

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 427,442,892
Total 13F shares: 926,000
Share change: +126,018
Total reported value: $1,429,279
Price per share: $1.56
Number of holders: 25
Value change: +$198,193
Number of buys: 5
Number of sells: 4

Quarterly Holders Quick Answers

What is CUSIP 528872302?
CUSIP 528872302 identifies LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 528872302:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
International S.c.a. Artal	3/4/5	Director, 10%+ Owner	— class O/S missing	136,180,481	$356,792,860	—	10 May 2024	3/4/5
Invus Global Management, LLC	13D/G 3/4/5	Artal Participations S.a r.l. · Director, 10%+ Owner	36%	154,734,327	$177,944,476	$0	29 Jan 2026	13D/G 3/4/5
Artal Group S.A.	13F	Company	32%	136,180,481	$156,607,553	—	31 Dec 2025	13F
Siren, L.L.C.	3/4/5 13F	Director, 10%+ Owner · Individual	9.1% from 13F	35,402,689	$92,755,045	—	25 Jul 2024	3/4/5 13F
Raymond Debbane	3/4/5	Director	— mixed-class rows	51,854,027 mixed-class rows	$77,568,743	+$722,624	25 Feb 2026	3/4/5
FMR LLC	13F 13D/G	Company	10% from 13D/G	37,834,207	$43,509,338	—	31 Dec 2025	13F 13D/G
Artal Participations S.a r.l.	3/4/5	Director, 10%+ Owner	— class O/S missing	408,435	$26,548,255	—	17 Feb 2026	3/4/5
VANGUARD GROUP INC	13F	Company	2.2%	9,606,549	$11,047,532	—	31 Dec 2025	13F
Invus US Partners LLC	3/4/5	Director, 10%+ Owner	— class O/S missing	5,782,749	$6,090,969	—	05 Aug 2022	3/4/5
MILLENNIUM MANAGEMENT LLC	13F	Company	1.1%	4,821,733	$5,544,993	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	0.75%	3,192,448	$3,671,316	—	31 Dec 2025	13F
Lonnel Coats	3/4/5	Chief Executive Officer, Director	— mixed-class rows	2,109,255 mixed-class rows	$3,507,748	—	28 Feb 2024	3/4/5
UBS Group AG	13F	Company	0.7%	3,007,237	$3,458,322	—	31 Dec 2025	13F
Sessa Capital IM, L.P.	13F	Company	0.7%	3,000,000	$3,450,000	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.58%	2,500,022	$2,876,410	—	31 Dec 2025	13F
CIBC Private Wealth Group LLC	13F	Company	0.46%	1,950,000	$2,242,500	—	31 Dec 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.4%	1,724,304	$1,982,950	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.4%	1,710,975	$1,967,621	—	31 Dec 2025	13F
Avicenna Life Sci Master Fund LP	3/4/5	Director, 10%+ Owner	0.36%	1,538,462	$1,815,385	—	02 Feb 2026	3/4/5
MARSHALL WACE, LLP	13F	Company	0.3%	1,262,367	$1,451,722	—	31 Dec 2025	13F
Ph.D. Michael Exton	3/4/5	Chief Executive Officer, Director	— mixed-class rows	2,598,629 mixed-class rows	$1,450,254	—	28 Feb 2026	3/4/5
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.28%	1,207,242	$1,388,329	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.25%	1,055,123	$1,213,391	—	31 Dec 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.23%	996,235	$1,146,000	—	31 Dec 2025	13F
Jeffrey L. Wade	3/4/5	President and COO	— mixed-class rows	729,441 mixed-class rows	$1,106,796	—	08 Jul 2024	3/4/5
GOLDMAN SACHS GROUP INC	13F	Company	0.22%	921,204	$1,059,385	—	31 Dec 2025	13F
Hennion & Walsh Asset Management, Inc.	13F	Company	0.21%	901,222	$1,036,405	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.21%	884,738	$1,017,449	—	31 Dec 2025	13F
Ishara Investments LP	13F	Company	0.21%	880,000	$1,012,000	—	31 Dec 2025	13F
Brian T. Crum	3/4/5	SVP, General Counsel & Secr.	— mixed-class rows	1,218,689 mixed-class rows	$805,650	—	28 Feb 2026	3/4/5
TWO SIGMA INVESTMENTS, LP	13F	Company	0.15%	637,308	$732,904	—	31 Dec 2025	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.15%	640,130	$732,000	—	31 Dec 2025	13F
Invesco Ltd.	13F	Company	0.14%	594,883	$684,115	—	31 Dec 2025	13F
B. Kassler Taub	3/4/5	SVP, Regulatory & QA	— mixed-class rows	431,995 mixed-class rows	$597,845	—	28 Feb 2024	3/4/5
Craig B. Granowitz	3/4/5	SVP, Chief Medical Officer	— mixed-class rows	1,247,870 mixed-class rows	$574,906	—	28 Feb 2026	3/4/5
Wendy E. McDermott	3/4/5	SVP, Human Resources	— mixed-class rows	942,032 mixed-class rows	$478,683	—	28 Feb 2026	3/4/5
Scott M. Coiante	3/4/5	SVP, Chief Financial Officer	— mixed-class rows	834,849 mixed-class rows	$476,949	—	28 Feb 2026	3/4/5
NORTHERN TRUST CORP	13F	Company	0.1%	412,164	$473,989	—	31 Dec 2025	13F
Lombard Odier SCmA Compagnie	13F	Individual	0.1%	410,000	$471,500	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13F	Company	0.07%	284,025	$326,629	—	31 Dec 2025	13F
Ph.D. Alan J. Main	3/4/5	EVP, Innov & Chem Sciences	— mixed-class rows	1,228,681 mixed-class rows	$318,646	—	28 Feb 2025	3/4/5
OMERS ADMINISTRATION Corp	13F	Company	0.06%	273,800	$314,870	—	31 Dec 2025	13F
ExodusPoint Capital Management, LP	13F	Company	0.06%	268,433	$308,698	—	31 Dec 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.06%	263,254	$302,742	—	31 Dec 2025	13F
Brian T. Corrigan	3/4/5	SVP, Regulatory & QA	— mixed-class rows	1,121,660 mixed-class rows	$300,602	—	13 Feb 2025	3/4/5
GROUP ONE TRADING LLC	13F	Company	0.05%	224,308	$257,954	—	31 Dec 2025	13F
Philippe Amouyal	3/4/5	Director	— mixed-class rows	478,292 mixed-class rows	$241,880	—	03 Jun 2025	3/4/5
Thomas Garner	3/4/5	SVP, Chief Commercial Officer	— mixed-class rows	454,260 mixed-class rows	$239,236	—	08 Feb 2024	3/4/5
BARCLAYS PLC	13F	Company	0.05%	194,743	$223,954	—	31 Dec 2025	13F
Robert J. Lefkowitz MD	3/4/5	Director	— mixed-class rows	130,080 mixed-class rows	$223,156	—	13 May 2024	3/4/5

Institutional Holders of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) as of Q1 2026

As of 31 Mar 2026, LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) was held by 25 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 926,000 shares. The largest 10 holders included Compagnie Lombard Odier SCmA, R Squared Ltd, Straight Path Wealth Management, WEDBUSH SECURITIES INC, KWB Wealth, Leonteq Securities AG, PINNACLE ASSOCIATES LTD, OPPENHEIMER & CO INC, Cambridge Investment Research Advisors, Inc., and Invera Wealth Advisors, LLC. This page lists 25 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

122

Q1 2026 holders

Holder diff

-97

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.